GlassScriptPhysician profile
Irfan Rasool Khan
NPI 1164714051
$2,501.46
in general payments reported to CMS, 2019-2025
20 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $282 · 2023: $834 · 2024: $620 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $374.62 | 2022-2024 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $330.46 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $244.71 | 2022-2025 | Cequa |
| Abbvie INC. | $238.75 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $186.52 | 2023-2025 | Eylea Hd, Eylea |
| Amgen INC. | $172.71 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $133.07 | 2023-2025 | Xipere, Miebo |
| Ani Pharmaceuticals, INC. | $132.96 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Allergan, INC. | $124.43 | 2021 | |
| Mallinckrodt Hospital Products INC. | $117.32 | 2023-2024 | Acthar |
| Genentech, INC. | $102.13 | 2023 | Vabysmo |
| Eyepoint US, INC. | $80.39 | 2022-2023 | |
| Harrow Eye, LLC | $68.10 | 2024-2025 | Vevye, Iheezo |
| Alcon Vision LLC | $55.50 | 2023-2025 | Tryptyr, Clareon, Rocklatan |
| Sandoz INC. | $31.80 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.50 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $24.19 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $21.15 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.81 | 2023 | |
| Ocular Therapeutix, INC. | $14.34 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.